Equitable Trust Co. Invests $676,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Equitable Trust Co. bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,635 shares of the company's stock, valued at approximately $676,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IDXX. International Assets Investment Management LLC increased its holdings in IDEXX Laboratories by 52,746.0% during the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock valued at $2,669,890,000 after buying an additional 527,460 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after buying an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd purchased a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $113,104,000. Vontobel Holding Ltd. increased its stake in shares of IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock worth $111,229,000 after purchasing an additional 213,731 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC increased its stake in shares of IDEXX Laboratories by 230.1% in the third quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company's stock worth $55,673,000 after purchasing an additional 76,809 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of analyst reports. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective for the company. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Finally, Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Price Performance

IDXX stock traded down $15.23 during trading on Friday, hitting $444.53. 553,751 shares of the company's stock traded hands, compared to its average volume of 714,172. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. The business has a fifty day simple moving average of $430.77 and a 200 day simple moving average of $453.31. The stock has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a P/E/G ratio of 3.47 and a beta of 1.37.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 over the last 90 days. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.